Newron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the FDA agreed a plan to address potential safety issues emerging from
Boehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known as NASH, a prime target for many pharma compani
Dutch biotech NorthSea Therapeutics has raised around $40 million in a series B financing round to help it develop novel strategies to treat the fatty liver disease known as NASH.<
